Rome, March 19 (beraking latest news Health) – AstraZeneca’s Covid-19 vaccine “continues to have a positive benefit-risk profile, with enormous potential in preventing infections and reducing deaths worldwide.” This is the conclusion of the WHO Expert Committee on Vaccine Safety (GACVS), at the end of the 3-day analysis of the data and information available on cases of thromboembolism and thrombocytopenia after vaccination with AstraZeneca. At present, “a causal link has not been established”.
“Available data do not suggest any general increase in clotting conditions such as deep vein thrombosis or pulmonary embolism following administration of Covid-19 vaccines. Reported rates of thromboembolic events after vaccines are in line with the expected number of diagnosis, both conditions occur naturally and are not uncommon. And they also occur as a result of Covid-19 “, explain the experts. As for the reports of rare forms of thrombosis, “it is not certain that these events, such as venous sinus thrombosis, were caused by vaccination”. Countries are “recommended”, in any case, “to continue to monitor the safety of all vaccines against Covid-19 and promote the reporting of suspected adverse events”.
COPYRIGHT today © breaking latest news